이
이명재 Chief Executive Officer
C-suite M
Discover the complete record of transactions filed by 이명재, Chief Executive Officer. Insider active across 2 companies, notably 인바이오. Cumulatively, 39 disclosures have been published. History available since 12 January 2026. The latest transaction was filed on 27 March 2026 (Purchase). Regulator: DART (FSS). All data is openly available.
Declarations 39 total
● 부사장 · Executives · 27 Mar 2026 · 인바이오 2,037 shares @ ₩2,044.9794 0.0000% mcap 40.3% of flow Share DART:20260330001269 Ideal exit: 22 Dec 2026 (T+270) ● 부사장 · Executives · 24 Mar 2026 · 인바이오 1,270 shares @ ₩2,013.011 0.0000% mcap 24.9% of flow Share DART:20260326000631 Ideal exit: 19 Dec 2026 (T+270) ● 부사장 · Executives · 11 Dec 2024 · 인바이오 1,547 shares @ ₩2,025.7388 0.0000% mcap 34.9% of flow Share DART:20260323001149 Ideal exit: 7 Sept 2025 (T+270) ● 전무이사 · Executives · 5 Jan 2026 · 인바이오 3,000 shares @ ₩2,054.0003 0.0000% mcap 100.0% of flow Share DART:20260310002718 Ideal exit: 2 Oct 2026 (T+270) ● 대표이사 · Executives · 12 Jan 2026 · 인바이오 8,998 shares @ ₩2,035.6664 0.0000% mcap 100.0% of flow Share DART:20260309001203 Ideal exit: 9 Oct 2026 (T+270) ● Executives · 9 Jan 2026 (filed)
● Executives · 2 Jan 2026 (filed)
● Executives · 29 Dec 2025 (filed)
● Executives · 22 Dec 2025 (filed)
● Executives · 15 Dec 2025 (filed)
● Executives · 8 Dec 2025 (filed)
● Executives · 1 Dec 2025 (filed)
● Executives · 8 Jan 2025 (filed)
● 대표이사 · Executives · 18 Dec 2024 (filed) · 인바이오 Share DART:20241218000148 Ideal exit: 14 Sept 2025 (T+270) ● 전무이사 · Executives · 13 Dec 2024 (filed) · 인바이오 Share DART:20241213000230 Ideal exit: 9 Sept 2025 (T+270) ● 대표이사 · Executives · 6 Dec 2024 (filed) · 인바이오 Share DART:20241206000231 Ideal exit: 2 Sept 2025 (T+270) ● 대표이사 · Executives · 21 Nov 2024 (filed) · 인바이오 Share DART:20241121000136 Ideal exit: 18 Aug 2025 (T+270) ● 부사장 · Executives · 19 Nov 2024 (filed) · 인바이오 Share DART:20241119000080 Ideal exit: 16 Aug 2025 (T+270) ● 전무이사 · Executives · 15 Nov 2024 (filed) · 인바이오 Share DART:20241115000199 Ideal exit: 12 Aug 2025 (T+270) ● 대표이사 · Executives · 14 Nov 2024 (filed) · 인바이오 Share DART:20241114000739 Ideal exit: 11 Aug 2025 (T+270) ● 전무이사 · Executives · 8 Aug 2024 (filed) · 인바이오 Share DART:20240808000224 Ideal exit: 5 May 2025 (T+270) ● 부사장 · Executives · 7 Aug 2024 (filed) · 인바이오 Share DART:20240807000227 Ideal exit: 4 May 2025 (T+270) ● 부사장 · Executives · 25 Jul 2024 (filed) · 인바이오 Share DART:20240725000080 Ideal exit: 21 Apr 2025 (T+270) ● 전무이사 · Executives · 24 Jul 2024 (filed) · 인바이오 Share DART:20240724000273 Ideal exit: 20 Apr 2025 (T+270) ● 전무이사 · Executives · 16 Jul 2024 (filed) · 인바이오 Share DART:20240716000162 Ideal exit: 12 Apr 2025 (T+270) 25 of 39 declarations
Load more (14 remaining) About 이명재 Lee Myung-jae is the Chief Executive Officer at 인바이오. He is responsible for the strategic and operational direction of the company. With significant experience in the sector, he plays a key role in innovation and product development. His leadership is essential for ensuring the growth and competitiveness of 인바이오.